Quince Therapeutics (QNCX) said late Tuesday that the enrollment in its phase 3 clinical trial of the neurological effects of eDSP system on Ataxia-Telangiectasia patients has exceeded 75%.
EDSP is comprised of dexamethasone sodium phosphate encapsulated in a patient's own red blood cells.
A total of 76 participants have been enrolled, including 65 participants in the six- to nine-year-old primary analysis population and 11 participants aged 10 years or above, the company said.
The company said it plans to submit a new drug application to the US Food and Drug Administration in H2 2026, subject to a positive outcome of the trial.
The company said it received the FDA's fast track designation for eDSP system for the treatment of patients with Ataxia-Telangiectasia, a rare neurodegenerative disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。